UPSA has acquired Sérélys Pharma

Sérélys Pharma

Sérélys Pharma develops and markets supplements designed to alleviate specific disorders linked to hormonal upheavals that women experience throughout their lives, such as premenstrual syndrome, post-partum discomfort and particularly those linked to aging. Its flagship products help relieve menopause-related discomforts such as hot flushes and mood disorders. Sérélys products are based on purified cytoplasmic pollen extracts from rigorously selected plants, obtained using its exclusive CyTonin technology. The treatment’s high effectiveness has been scientifically proven and measured by over thirty clinical studies. They are 100% natural, with no hormones or substances with phytoestrogenic activity. Based in Monaco and selling in more than 50 countries, Sérélys Pharma has very significant growth potential, given its exclusive technology and the scale of unmet needs in the natural feminine wellbeing market.

The Deal

The acquisition of Sérélys presents a unique opportunity for UPSA to expand its footprint in the fast-growing women’s health segment, addressing significant unmet needs with natural, hormone-free solutions. Sérélys’ established market leadership, particularly in Europe, complements UPSA’s strong presence and extensive salesforce network. Leveraging UPSA’s expertise in product innovation and brand building, this partnership will unlock geographic expansion across UPSA’s 60-country distribution network and leverage its marketing and sales capabilities to accelerate growth. This promising acquisition, UPSA’s first in over 30 years, is a significant step in its growth plan and will help to make UPSA a major international player in family health and women’s well-being.

Our Perspective

François Rispoli, Lincoln International Managing Director who led the transaction, commented, “We are thrilled to have supported UPSA in this acquisition, working alongside its team to help make this deal happen and directing continued efforts to establish our client as the preferred partner for the next growth phase of this exciting clinically backed, market-leading brand. The acquisition of Sérélys underscores UPSA’s ambition in the women’s health market, setting the stage for continued success and growth in family health and women’s wellbeing for the group.”

UPSA

Founded in 1935, UPSA is a French medium-sized company that designs, manufactures and markets self-medication products and medical devices, operating one of the largest pharmaceutical manufacturing sites in France, located in Agen. A committed brand that has been working with patients and pharmacists for almost 90 years, its expertise covers five therapeutic areas: pain and fever (a long-standing specialty), ENT and respiratory tract, digestion, sleep disorders and vitality. As the largest private employer in its department, UPSA is the embodiment of local roots and of the defense of ‘Made in France’ expertise with an international reputation. The company employs 1,700 people, including 1,600 in France, and generates 3,500 indirect jobs. With a presence in more than 60 countries, mainly in Europe, French-speaking Africa, China and Vietnam, UPSA generates sales of almost €500 million and exports more than 55% of its volumes internationally from Agen every year. In 2024, it was awarded the B Corp label, which recognizes companies that meet high standards in terms of social and environmental performance, transparency and responsibility.

Share: